Introduction
============

Colorectal cancer (CRC) is one of the most common malignant tumors and places an enormous burden on the society. It was estimated that 1.4 million new cases were diagnosed worldwide in 2012,^[@bib1]^ of which, more developed countries accounted for the larger proportion. In contrast to incidence, mortality rates of CRC have been found to decrease in numerous countries, which most likely benefits from early detection.^[@bib2]^ It is predicted that a total of 277,000 new CRC cases and 203,000 CRC-induced deaths in United States will be averted from 2013 to 2018 if National Colorectal Cancer Roundtable reaches the goal of increasing the prevalence of CRC screening to 80% by 2018.^[@bib3]^ Although there are various guideline-recommended methods one can choose for detection, the compliance remains low. The data in 2013 showed that only about 57% of eligible adults adhered to screening recommendations provided by US Preventive Services Task Force (USPSTF).^[@bib4]^ There are many reasons for low adoption for CRC detection. Obstacles specific to colonoscopy include aversion to bowel preparation, discomfort during the procedure, pre- and post-procedure time requirements, and costs.^[@bib5]^ Guiac-based fecal occult blood tests or fecal immunochemical tests (FITs) are easier to be accepted. However, both methods continue to be underutilized and have relatively low diagnosis value.^[@bib6]^ Since the currently utilized methods have various limitations and there is no other information available for detection, it is very important to introduce better and more patient-friendly approaches, especially blood testing, for detecting CRC.^[@bib7]^

It is known that CRC occurs due to the genetic and epigenetic alterations of intestinal epidermal cells.^[@bib8]^ Therefore, the determination of specific molecular markers targeting the changes may be a promising method for detecting early CRC. Aberrant methylation of tumor DNA sequences has been found in various genes, of which, methylated *Septin 9* (m*SEPT9*) DNA is validated to be able to effectively diagnose CRCs from normal blood using real-time PCR.^[@bib9]^ *SEPT9*, a member of the *Septin* family, has been found to function in cytokinesis and remodeling cytoskeletal.^[@bib10]^ *mSEPT9* was found to be correlated with carcinogenesis.^[@bib10]^ Multiple research assays have been developed to identify *mSEPT9* in circulating plasma by PCR amplification. A number of case--control studies, which encompassed thousands of clinical samples,^[@bib9],\ [@bib11],\ [@bib12],\ [@bib13]^ have been performed to verify the accuracy of *mSEPT9* for CRC detection. In these studies, the sensitivity and specificity ranged from 69 to 79% and 82 to 99%, respectively. However, a prospective study (PRESPET NCT00855348) published later in 2014, which recruited almost 8000 samples, showed that the sensitivity was only 50.9%, lower than the expected data.^[@bib14]^ Until then, it still lacked convincing evidence to translate such methods from research into clinical practice.

Given that determination of *mSEPT9* in blood has a promising future for CRC screening, existing researches and guidelines still fall short of giving detailed instructions to improve clinical applications which may be a result of insufficient evidence or underestimated diagnostic value. There are various methods (MethyLight, MSP-DHPLC, MS-HRM) and assays used in detecting *mSEPT9*, most of which are claimed to have high value. Epi proColon itself has two generations of assays and three inspection methods. The limitations above may hinder the understanding of optimal utilization strategy until more accurate and detailed explanations are provided. Therefore, we have performed a systematic review and meta-analysis of the diagnostic accuracy of *mSEPT9* in order to explore the optimal method and kit for CRC detection.

Methods
=======

Criteria for considering studies for this review
------------------------------------------------

We included all the primary studies which were performed to determine the diagnostic accuracy of the index test and compared them with the reference standard ones in CRC screening. The types of studies included cohort studies, cross-sectional studies and case--control studies from which we can extract data for true-positives (TP), true-negatives (TN), false-positives (FP), and false-negatives (FN). We excluded unpublished studies that were only reported in abstracts, or studies with inadequate data to construct a two-by-two table.

To estimate *mSEPT9* in peripheral blood, the index test should be the methods and kits used, while the reference test should be colonoscopy. Any studies that estimated *mSEPT9* in stools or other tissues were not included, neither were the ones using other comparator tests.

Search strategy
---------------

We searched the following literature databases for publications from their inception to 1 June 2016: Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Library, Medline via PubMed, EMBASE via embase.com, China National Knowledge Infrastructure Database (CNKI), Chinese Biomedical Literature Database (CBM), Chinese Scientific Journal Database (VIP database), and Wanfang database. To improve recall ratio in retrieval, the search strategy consisted of medical subject heading terms, keywords and free terms related to the marker (septin 9 or sept 9, etc.) combined with the disease (colorectal neoplasms, colon cancer, or rectum cancer, etc.). The search language was restricted to English and Chinese. (See [Supplementary Information 1](#sup1){ref-type="supplementary-material"}).

We manually retrieved and examined the reference lists of relevant articles for additionally eligible studies. We also searched OpenGrey.eu for potential grey studies and clinical trials registry platforms such as ICRTP for ongoing and recently completed ones.

Data collections and analysis
-----------------------------

### Selection of studies

We created a database using Endnote X7 and uploaded all studies obtained from electronic searches and other sources to the database, excluding duplicates. Two researchers (SYM and CY) independently screened the searching results, including the titles, abstracts, and keywords. The articles that measured up to the inclusion criteria for this review were included for full-text screening. Disagreements were resolved by discussion or consulting with a third researcher (XS).

### Data extraction and management

Two researchers (YM and YF) independently performed data extraction from the included studies. The authors were contacted when more information was needed. The key information was as follows: General information about the studies, included first author\' name, year, country, study type, etc.Demographic information, including gender, ethnicity, age, CRC stage and differentiation, pathology types, and sample size.Index test information included cut-off point, methods and kits used.Outcomes included TP, FP, TN and TN.

### Assessment of methodological quality

Another two researchers (YM and LY) independently assessed the quality of each study by using the Quality Assessment of Diagnostic Accuracy Studies-2(QUADAS-2) tool, which consisted of four domains: patient selection, index test, reference standard, and flow of patients and timing of the tests.^[@bib15]^ All four domains were used to assess risk of bias and the first three domains were used to assess study applicability. Any disagreements were resolved by consensus or consulting the arbitrator (XS).

### Statistical analysis and synthesis

We performed a bivariate mixed effect model to summarize the sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio (DOR) of *mSEPT9* in CRC screening. We also conducted a hierarchical summary receiver--operator characteristic curve (HSROC) to estimate the area under the curve (AUC).We investigated potential heterogeneity by calculating the Cochran\' Q statistic and *I*^2^ for other causes of heterogeneity. If the *P* value of the Q-test was ≥0.05 or the *I*^2^ value was ≤50%, it suggested that no significant heterogeneity existed.

If significant heterogeneity existed, we investigated the causes of heterogeneity by performing subgroup analysis and meta-regression when sufficient studies were available. The following categorical covariates were used: assays or methods of index test, race, CRC stage and differentiation, pathology types, etc. Spearman correlation coefficients between sensitivity and 1-specificity were also estimated for the threshold effect. Furthermore, Deeks\' funnel plot was used to estimate the risk of publication bias, and a *P* value \<0.05 indicated high risk of bias.

Results
=======

Search results
--------------

A total of 230 articles were initially retrieved using the search strategy above, of which, 228 were selected from electronic databases and two were identified through the manual screening of relevant articles in reference lists. One hundred and forty-nine articles were included for title and abstract screening after removing 81 duplications. Then, 24 were excluded due to inappropriate types and 90 were excluded for the reason that the studies were not related to our topic. As a result, 35 articles were suitable for full-text assessment. After full-text reading, 25 articles^[@bib9],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19],\ [@bib20],\ [@bib21],\ [@bib22],\ [@bib23],\ [@bib24],\ [@bib25],\ [@bib26],\ [@bib27],\ [@bib28],\ [@bib29],\ [@bib30],\ [@bib31],\ [@bib32],\ [@bib33],\ [@bib34],\ [@bib35]^ were included in this meta-analysis. (See [Figure 1](#fig1){ref-type="fig"}).

Characteristic of included studies
----------------------------------

[Table 1](#tbl1){ref-type="table"} outlines the characteristic of include studies. A total of 9927 samples from 25 studies were used in our meta-analysis, of which 2975 were CRCs and 6952 were adenoma, polyps or other colorectal diseases. The studies were conducted in seven countries from 2008 to 2016, including the United States, China, Germany, Hungary, Russia, Korea, and Denmark. Most of the studies were case--control studies in design, while four of them were prospective studies. Various types of methods and assays were employed, and Epipro Colon was utilized the most (18/25). Seventeen studies provided diagnostic results among TNM stages and four offered the data in different differentiations. FITs were used as combined methods to estimate the diagnostic accuracy in six studies.

Study quality
-------------

[Figure 2](#fig2){ref-type="fig"} show the results of the quality appraisal of 25 studies that were included. Only two studies show a low risk of bias in all four domains of QUADAS 2. 21 studies inappropriately excluded "difficult-to-diagnose" patients, therefore the risk of bias of patient selection was rated as high. Seven studies had insufficient data about threshold setting and two selected their cut-off points by adjusting during their studies. As methylated *SEPT9* is an objective index test, we omitted the signaling question about blinding the result of index test to reference one. Two studies offered insufficient data about blinding of reference standard, resulting in unclear risk in this domain. Seven studies showed unclear risk of flow and timing, because colonoscopy was examined before recruitment and intervals could not have been estimated.

Eight studies showed high concern of applicability for the reason that they only enrolled healthy persons in control group. Seven studies had unclear concern because the threshold and assay were not interpreted in details. All of the studies showed low concern about reference standard.

Diagnostic accuracy and subgroup analysis
-----------------------------------------

Spearman correlation coefficient was −0.310 and *P* value was 0.131. The proportion of heterogeneity likely due to threshold effect was 0.02, which meant there existed no significant threadhold effect among included 25 studies. [Figure 3](#fig3){ref-type="fig"} indicates the forest plot of overall pooled sensitivity and specificity. According to the bivariate mixed effect model, the pooled sensitivity and specificity was 0.71 (95% confidence interval (CI): 0.67--0.75) and 0.92 (95%CI: 0.89--0.94), respectively. [Figure 4](#fig4){ref-type="fig"} (Part A) shows the HSROC and its AUC (0.88, 95%CI: 0.85--0.91). The HSROC figure is symmetrical (*Z*=1.62 and *P*=0.105) and it presents significance in diagnostic value (*λ*=3.07).

Furthermore, subgroup analysis was therefore performed by ethnicity, study type, assay, tumor stage and differentiation, combined method and precancerosis (see [Table 2](#tbl2){ref-type="table"}). We also conducted subgroup analysis based on assay or method which was used in included studies and the results equaled that of Epipro Colon assay and other methods (MethyLight, MSP-DHPLC, MS-HRM, etc.) but differed between generation 1 and generation 2 Epipro colon assay. The pooled sensitivity was 0.76 and the specificity was 0.94 in the generation 2 assay, higher than that of generation 1.

In addition, data was further extracted and analyzed by the groups of disease stages and combined methods. The pooled sensitivity, specificity, LR+, LR−, DOR, and AUC are 0.79, 0.93, 11.0, 0.22, 49, and 0.92 in stage IV, respectively, which shows the highest diagnosis value, followed by stages III, II, and I. Similarly, CRC cases with low differentiation were more likely detected than moderate and high one. Three studies combined *mSPET9* with FIT in parallel tests to estimate diagnosis accuracy and the results showed higher sensitivity (0.94) and lower specificity (0.68) than using mSPET9 alone. There was not enough data to combine carcinoembryonic antigen (CEA) or other methods in testing diagnostic accuracy. Twelve studies provided the details about results in adenomas and polyps. The pooled sensitivity was 0.15 and 0.05 in adenomas and polyps, respectively, both indicating low positive ratio of *mSPET9* detection. Moreover, the pooled sensitivity was 0.23 for larger size (large than 1 cm) polyps or adenomas, which is higher than smaller ones (0.09; see [Table 2](#tbl2){ref-type="table"}).

Since [Figure 3](#fig3){ref-type="fig"} indicates significant heterogenity of sensetivity and specificity after computing the Cochran\' Q statistic and *I*^2^ (both *P* value \<0.05), meta-regression was therefore conducted to trace the causes. The result shows that study types, kits used (Epipro colon or not), country (Asia or not), sample size (\> or \<300) and risk of bias of included studies all lead to the heterogeneity of sensitivity and specificity in a single variable model, of which whether the studies were performed in Asian countries or not was significant in joint model (*P*=0.01; see [Figure 5](#fig5){ref-type="fig"}).

[Figure 6](#fig6){ref-type="fig"} presents symmetry in Deeks\' funnel plot (*P*=0.41) and indicates that there exists no significant publication bias in the included studies.

Discussion
==========

Recently, USPSTF updated its recommendations and initially reviewed the evidence on the efficacy of detection CRCs with *mSEPT9*.^[@bib36]^ In our systematic review, we estimated that the pooled sensitivity and specificity was 0.71 and 0.92, respectively, proving to be reliable for CRC detection. The results were apparently higher than those in PRESEPT study,^[@bib14]^ which may owed to recruiting early asymptomatic CRC patients for analysis. The systematic review also performed stage and differentiation-related analysis in detection, and [Table 2](#tbl2){ref-type="table"} presents an apparent positive correlation between the detection rates of CRC and stage degrees. The results indicates that advanced stage CRCs are easier to be detected by *mSEPT9* than early stage. The trend was similarly observed in tumor differentiation. Low-differentiation CRCs has much higher sensitivity than high differentiation ones. The results showed Asia Group had higher sensitivity than other continents. However, the results from Korea^[@bib18]^ showed obvious lower sensitivity (0.363). The discrepancy might have occurred due to the potential racial differences and kit variations.^[@bib37]^

In our subgroup analysis, we tried to explore the optimal method and assay for *mSEPT9*. 20 studies investigated the accuracy of Epi proColon and only four of included studies focused on other assay kits (mainly using the MytheLight method). Both assays presented similar results, but the Epipro Colon was found to be described in details and thus easier for clinicians to operate. The second generation of Epipro Colon has received approval from the US Food and Drug Administration^[@bib38]^ and was reported to have resolved many technical hurdles and improved in several aspects, such as employing a novel bisulfite DNA conversion and purification technology^[@bib39]^ as well as a new real-time PCR reaction.^[@bib13]^ Two different types of algorithms were applied for Epicolon Colon in the studies and the results were different in sensitivity and specificity. Sensitivity was high using a 1/3 algorithm test but the specificity was low. Although sensitivity was low using a 2/3 algorithm test, it had a high true negative rate. Since it is more important to improve the capability in excluding non-cancer samples and avoiding the rate of misdiagnosis, 2/3 algorithm is recommended for CRCs detection.

As a first blood-based detection method recommended for CRC, can *mSEPT9* really improve compliance? The data results from a German research ensured the practicability, in which 83% of patients were willing to accept *mSEPT9* test, which is higher than colonoscopy (37%) and stool test (15%).^[@bib40]^

Even though the systematic review concluded an encouraging result of *mSPET9* in CRC detection, it still has several limitations. First of all, FIT is currently widely used in CRC screening. However, due to lack of appropriate studies for further analysis, we did not provide further information about sensitivity and specificity in comparison between *mSPET9* and FIT. Secondly, despite the diagnostic value of detecting advanced stage CRCs (III--IV), the analysis that were focused on early stage of CRC (Stage I) and adenomas or polyps showed low sensitivity. It turned out the diagnostic value of *mSEPT9* may, to some degree, be limited in precancerous lesions and CRC in Stage I. However, *mSEPT9* was shown to have low misdiagnosis rate and sensitivity may be improved when combined with FIT. Thirdly, as different methods were used for detecting *mSEPT9*, we did not subgroup analyze the optimal threshold for every method other than Epipro Colon. Three different cut-off points were used for this assay, of which Ct\<45.0 was the most utilized. The sensitivity was 0.70 when Ct\<45.0 was used, slightly lower than Ct\<41.0, indicating Ct\<45.0 may be more sensitive for utilization. But it still need further study to verify it as the best threshold. Fourthly, this meta-analysis did not include any language other than Chinese and English. Restriction in languages may bring about a potential risk of publication bias. In terms of methodological quality, most studies that were included were case--control in design and excluded "difficult-to-diagnose" patients, which may lead to a risk of bias in patient selection and overestimation of diagnostic accuracy.^[@bib18]^ Finally, although it was reported that *mSEPT9* could be employed as a predictor of CRC recurrence, metastasis and survival,^[@bib18],\ [@bib41]^ there is insufficient data for synthesis in our meta-analysis in order to draw robust conclusions about the value as a follow-up marker.

In conclusion, our systematic review suggests that *mSEPT9* can be used as an effective marker for blood-based CRC detection. Based on current evidence, the second generation Epipro Colon (Epigenomics) could be used as the optimal assay kit with 2/3 algorithm. In addition, the review revealed that a larger sample size and more prospective studies were needed to further verify the diagnostic value of *mSEPT9*.

Study Highlights
================
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###### Characteristic of included studies

  **NO**   **Study**      **Year**   **Country**    **Sample size**   **TP**   **TN**   **FP**   **FN**    **Cut-off value**   **Algorithm**  **Study type**      **Assay method**   **Kit used**
  -------- -------------- ---------- -------------- ----------------- -------- -------- -------- -------- ------------------- --------------- ------------------- ------------------ ------------------
  1        Yu D           2015       China          123               57       46       7        13            Ct\<45. 0           2(3)       Case--control       RT-PCR             Epipro Colon 2.0
  2        Jin P          2015       China          476               101      298      43       34            Ct\<45. 0           2(3)       Case--control       RT-PCR             Epipro Colon 2.0
  3        He Q           2015       China          100               38       48       2        12             PMR≥ 4%             NA        Case--control       MethyLight         NA
  4        He N           2015       China          281               54       196      9        22            Ct\<40. 5           2(3)       Case--control       RT-PCR             Epipro Colon 2.0
  5        Wang Z         2012       China          56                25       18       2        11             PMR≥1%              NA        Case--control       MS-HRM             NA
  6        Li SJ          2015       China          161               66       65       5        25               NA               2(3)       Case--control       RT-PCR             Epipro Colon 2.0
  7        Wu D           2016       China          1031              223      697      43       68            Ct\<45. 0           1(1)       Prospective study   RT-PCR             Epipro Colon 2.0
  8        Kang Q         2014       China          132               60       51       1        20               NA               2(3)       Case--control       RT-PCR             Epipro Colon 2.0
  9        Ding QQ        2015       China          262               60       171      9        22            Ct\<45. 0           2(3)       Case--control       RT-PCR             Epipro Colon 2.0
  10       Warren JD      2011       US, Russia     144               38       93       1        12            Ct\<45. 0           2(3)       Case--control       RT-PCR             Epipro Colon 1.0
                          2011       USA, Russia    144               45       83       11       5             Ct\<41. 0           1(3)       Case--control       RT-PCR             Epipro Colon 1.0
                          2011       USA, Russia    144               35       94       0        15            Ct\<45. 0           3(3)       Case--control       RT-PCR             Epipro Colon 1.0
  11       Johnson DA     2014       USA            301               74       163      37       27               NA                NA        Prospective study   RT-PCR             Epipro Colon 1.0
  12       Lee HS         2013       Korea          197               37       87       9        64               NA               1(3)       Case--control       RT-PCR             Abbott Molecular
  13       Lucia PC       2014       USA            367               244      20       1        102              NA                NA        Case--control       RT-PCR             Epipro Colon 1.0
  14       Marc T         2010       Germany        161               24       98       30       9                NA               2(3)       Case--control       Heavy MethyLight   NA
                          2010       Germany        161               27       81       47       6                NA               1(3)       Case--control       Heavy MethyLight   NA
  15       Grutzmann R    2008       Germany        831               193      403      50       185              NA               2(3)       Case--control       RT-PCR             Epipro Colon 1.0
  16       deVos T        2009       Germany        514               138      282      45       49             3.4ug/L            1(3)       Case--control       RT-PCR             Epipro Colon 1.0
                          2009       Germany        514               105      316      11       82             3.4ug/L            2(3)       Case--control       RT-PCR             Epipro Colon 1.0
  17       Church TR      2013       Germany, USA   1510              27       1331     126      26             Ct\<50             1(2)       Prospective study   RT-PCR             Epipro Colon 1.0
  18       Toth K         2012       Hungary        184               73       91       1        19            Ct\<40. 5           2(3)       Case--control       RT-PCR             Epipro Colon 2.0
                          2012       Hungary        184               88       78       14       4             Ct\<40. 5           1(3)       Case--control       RT-PCR             Epipro Colon 2.0
  19       Toth K         2014       Hungary        84                30       40       10       4            PMR≥ 0.01%            NA        Case--control       RT-PCR             Epipro Colon 2.0
  20       Su XL          2014       China          234               152      58       4        20             MSP≥1%              NA        Case--control       MSP-DHPLC          NA
  21       Potter NT      2014       USA            1544              30       1182     318      14            Ct\<45. 0           1(3)       Prospective study   RT-PCR             Epipro Colon 2.0
  22       Lofton-Day C   2008       USA            312               92       154      25       41               NA                NA        Case--control       MethyLight         NA
  23       He Q           2010       China          352               136      164      6        46             PMR≥ 4%             NA        Case--control       MethyLight         NA
  24       Ørntoft MW     2015       Denmark        470               93       282      60       35            Ct\<45. 0           1(3)       Case--control       RT-PCR             Epipro Colon 2.0
                          2015       Denmark        470               75       328      14       53            Ct\<45. 0           2(3)       Case--control       RT-PCR             Epipro Colon 2.0
  25       Ahlquist DA    2011       USA            100               18       54       16       12            Ct\<45. 0           1(3)       Case--control       RT-PCR             Epipro Colon 1.0

MS-HRM, methylation sensitive high-resolution melting; MSP-DHPLC, methylation spective polymerase chain reaction; RT-PCR, real-time polymerase chain reaction.

###### Subgroup analysis

  **Analyses**                   **Sensitivity (95%CI)**   **Specificity (95%CI)**   **LR+ (95%CI)**     **LR− (95%CI)**     **DOR (95%CI)**     **AUC**
  ------------------------------ ------------------------- ------------------------- ------------------- ------------------- ------------------- ---------
  Overall                        0.71 (0.67--0.75)         0.92 (0.89--0.94)         8.6 (6.2--11.8)     0.31 (0.27--0.37)   27 (18--42)         0.88
                                                                                                                                                  
  *Ethnicity*                                                                                                                                    
   Europe                        0.70 (0.51--0.83)         0.94 (0.84--0.98)         11.2 (4.1--30.4)    0.32 (0.19--0.55)   35 (10--120)        0.90
   America                       0.71 (0.68--0.74)         0.79 (0.78--0.81)         3.4 (3.2--3.7)      0.30 (0.33--0.41)   9 (8--11)           0.82
   Asia                          0.75 (0.71--0.78)         0.94 (0.90--0.96)         11.6 (7.7--17.5)    0.27 (0.23--0.31)   43 (27--68)         0.79
                                                                                                                                                  
  *Study design*                                                                                                                                 
   Case--control                 0.72 (0.67--0.76)         0.92 (0.89--0.95)         9.5 (6.6--13.7)     0.31 (0.25--0.37)   31 (19--50)         0.89
   Cross-sectional               0.69 (0.59--0.77)         0.88 (0.80--0.93)         5.7 (3.3--9.9)      0.35 (0.26--0.48)   16 (8--34)          0.84
                                                                                                                                                  
  *Assay or method*                                                                                                                              
   Epipro Colon 1.0+2.0          0.71 (0.66--0.76)         0.93 (0.89--0.95)         10.2 (6.6--15.6)    0.31 (0.26--0.37)   33 (20--55)         0.88
   Epipro Colon 1.0              0.63 (0.54--0.71)         0.94 (0.87--0.97)         9.8 (4.6--20.9)     0.39 (0.31--0.50)   25 (10--62)         0.83
   Epipro Colon 2.0              0.76 (0.73--0.79)         0.93 (0.88--0.96)         10.4 (6.13--17.6)   0.26 (0.23--0.30)   39.60 (10--62)      0.77
   MethyLight                    0.72 (0.67--0.77)         0.91 (0.80--0.96)         8.0 (3.3--19.3)     0.30 (0.24--0.38)   26 (9--76)          0.78
                                                                                                                                                  
  *Algorithm for Epi proColon*                                                                                                                   
   1/3 algorithm                                                                                                                                  
   2/3 algorithm                 0.70 (0.64--0.75)         0.94 (0.91--0.97)         12.3 (7.3--20.8)    0.32 (0.26--0.39)   39 (21--72)         0.88
                                                                                                                                                  
  Stage                          0.74 (0.59--0.85)         0.84 (0.78--0.88)         4.5 (3.4--6.1)      0.31 (0.19--0.51)   14 (8--28)          0.87
   Stage I                       0.45 (0.38--0.53)         0.93 (0.90--0.95)         6.4 (4.0--10.1)     0.59 (0.50--0.68)   11 (6--19)          0.72
   Stage II                      0.70 (0.60--0.79)         0.93 (0.90--0.95)         10.0 (6.1--16.4)    0.32 (0.23--0.45)   31 (14--69)         0.92
   Stage III                     0.76 (0.64--0.86)         0.93 (0.90--0.95)         10.8 (6.5--17.9)    0.25 (0.15--0.41)   43 (17--110)        0.94
   Stage IV                      0.79 (0.69--0.87)         0.93 (0.90--0.95)         11.0 (7.3--16.6)    0.22 (0.15--0.34)   49 (24--101)        0.92
                                                                                                                                                  
  *Differentiation*                                                                                                                              
   High                          0.31 (0.12--0.59)         0.95 (0.93--0.96)         6.1 (2.6--14.6)     0.73 (0.51--1.04)   8 (3--29)           0.95
   Moderate                      0.73 (0.68--0.78)         0.95 (0.93--0.96)         14.5 (10.8--19.3)   0.28 (0.23--0.34)   51 (34--76)         0.94
   Low                           0.90 (0.83--0.95)         0.95 (0.93--0.96)         17.8 (13.4--23.8)   0.10 (0.06--0.19)   173 (84--354)       0.98
                                                                                                                                                  
  *Combined method*                                                                                                                              
   Sept 9+FIT (PT)               0.94 (0.89--0.97)         0.68 (0.56--0.78)         2.9 (2.2--4.0)      0.08 (0.04--0.15)   36 (21--62)         0.91
                                                                                                                                                  
  *Precancerosis*                                                                                                                                
   Adenoma                       0.15 (0.11--0.19)         0.90 (0.85--0.94)         1.5 (1.0--2.4)      0.94 (0.89--1.00)   2 (1--3)            0.36
   Polyp                         0.05 (0.03--0.08)         0.94 (0.90--0.97)         0.83 (0.36--1.94)   1.01 (0.96--1.06)   0.82 (0.34--2.0)    0.15
                                                                                                                                                  
  *Polyp/adenoma size*                                                                                                                           
   \>1 cm                        0.23 (0.17--0.29          0.91 (0.89--0.93)         2.56 (1.77--3.71)   0.85 (0.78--0.92)   3.01 (1.93--4.71)   0.68
   ≤1 cm                         0.09 (0.06--0.14)         0.91 (0.89--0.93)         1.06 (0.66--1.70)   0.99 (0.95--1.04)   1.07 (0.64--1.79)   0.51

AUC, area under the curve; CI, confidence interval; DOR, diagnostic odds ratio; FIT, fecal immunochemical test; LR+, positive likelihood ratio; LR−, negative likelihood ratio; PT, parallel test.
